AfshinSalsaliMD

Endocrinology • New Brunswick, NJ

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. Salsali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salsali's full profile

Already have an account?

Office
125 Paterson St
Ste 5200
New Brunswick, NJ 08901
Phone+1 732-235-7219

Education & Training

University of Vermont Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2001 - 2003
Quinnipiac University Frank H. Netter MD School of Medicine/St Vincent's Medical CenterResidency, Internal Medicine, 1998 - 2001
Tehran University of Medical Sciences School of MedicineClass of 1991

Certifications & Licensure

ND State Medical License Current
NJ State Medical License 2008 - 2025
VT State Medical License 2001 - 2012

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Publications & Presentations

PubMed

113 citations
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
William T. Abraham, JoAnn Lindenfeld, Piotr Ponikowski, Piergiuseppe Agostoni, Javed Butler
European Heart Journal. 2021-02-11
34 citations
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepi...
Sven Kohler, Stefan Kaspers, Afshin Salsali, Cordula Zeller, Hans-Juergen Woerle
Diabetes Care. 2018-08-01
44 citations
A review of types 1 and 2 diabetes mellitus and their treatment with insulin.
Afshin Salsali, Muriel Nathan
American Journal of Therapeutics. 2006-07-01

Journal Articles

Empagliflozin Compared with Glimepiride in Metformin‐Treated Patients with Type 2 Diabetes: 208‐Week Data from a Masked Randomized Controlled Trial
Afshin Salsali, MD, Diabetes, Obesity and Metabolism

Press Mentions

Empagliflozin Lowers High Blood Pressure, Blood Sugar in DiabeticsJune 23rd, 2014